deepCDR: Advancing the therapeutic antibody discovery process

Currently, drug developers searching for new therapeutic antibodies use time-consuming experimental screening processes that can take years to develop a handful of candidates ready for clinical trials. Simon Friedensohn and his deepCDR co-founders combine gene editing, deep sequencing, and deep learning to accelerate the therapeutic antibody discovery process. An interview.